Will more complete inhibition of the RAAS with angiotensin receptor blockade improve survival following myocardial infarction?

JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

Volumn 1, Issue SUPPL. 2, 2000, Pages 41-43

  Pfeffer, Marc A ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Angiotensin II receptor blocker; Long term trial; Myocardial infarction; OPTIMAAL; VALIANT; Valsartan

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; DRUG DERIVATIVE; TETRAZOLE DERIVATIVE; VALINE; VALSARTAN;

DRUG EFFECT; HEART INFARCTION; HUMAN; MORTALITY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SURVIVAL; TREATMENT OUTCOME;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; HUMANS; MYOCARDIAL INFARCTION; RENIN-ANGIOTENSIN SYSTEM; SURVIVAL; TETRAZOLES; TREATMENT OUTCOME; VALINE;

EID: 0346677458     PISSN: 14703203     EISSN: None     Source Type: Journal    
DOI: 10.3317/jraas.2000.056     Document Type: Article

References (10)

1. Pfeffer JM, Pfeffer MA, Braunwald E. Influence of chronic captopril therapy on the infarcted left ventricle of the rat. Circ Res 1985;57:84-95.
2. Pfeffer MA. ACE inhibition in acute myocardial infarction. [Editorial]. N Engl J Med 1995;332:118-20.
3. Flather MD, Yusuf S, Kober L et al. for the ACE-inhibitor Myocardial Infarction Collaborative Group. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients Lancet 2000;355:1575-81.
4. Pfeffer MA, Braunwald E, Moyé LA et al. on behalf of the SAVE Investigators. The effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the Survival and Ventricular Enlargement Trial. N Engl J Med 1992;327:669-77.
5. Yusuf S, Pepine CJ, Garces C et al. Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions. Lancet 1992;340:1173-8.
6. Yusuf S, Sleight P, Pogue JE et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342:145-53.
7. Gainer JV, Morrow JD, Loveland A, King DJ, Brown NJ. Effect of bradykinin-receptor blockade on the response to angiotensin-converting-enzyme inhibitor in normotensive and hypertensive subjects. N Engl J Med 1998;339:1285-92.
8. Dickstein K, Kjekshus J. Comparison of the effects of losartan and captopril on mortality in patients after acute myocardial infarction: the OPTIMAAL trial design. Optimal Therapy in Myocardial Infarction with the Angiotensin II Antagonist Losartan. Am J Cardiol 1999;83:477-81.
9. Pfeffer MA, McMurray J, Leizorovicz A et al. for the VALIANT Investigators. Valsartan in Acute Myocardial Infarction Trial (VALIANT): Rationale and Design. Am Heart J 2000;140: 727-34.
10. Pitt B, Segal R, Martinez FA, Meurers G et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 1997;349:747-52.